ImmunoPrecise Antibodies Ltd.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- ImmunoPrecise Antibodies Ltd., operating through its subsidiaries across North America and Europe, is a biotechnology firm specializing in the discovery and development of therapeutic antibodies. The company has shifted its strategic focus to integrate artificial intelligence (AI) and proprietary technologies to accelerate biotherapeutic drug discovery. ImmunoPrecise offers an end-to-end suite of capabilities for the development of next-generation antibody therapeutics. Its core services include custom antibody discovery and development, leveraging advanced platforms like its proprietary LENSai™ platform and HYFT® technology for in silico and wet-lab approaches. These tools aid in areas such as target analysis, immunization, antibody characterization, developability profiling, optimization, and preclinical services. While a portion of its revenue still comes from product sales like antibodies, enzymes, and proteins for research, the company's primary revenue model is now driven by providing specialized antibody discovery and development services to pharmaceutical and biotechnology companies on a fee-for-service basis. Additional income streams are anticipated from milestone payments, royalties, and licensing fees derived from its internal therapeutic pipeline candidates and proprietary technologies. The target market consists of pharmaceutical and biotechnology companies globally seeking advanced solutions for complex drug discovery challenges. Recently, ImmunoPrecise has undertaken significant strategic initiatives, including a rebranding to MindWalk and a change of its NASDAQ ticker to "HYFT," signaling its evolution into a Bio-Native AI platform company. The company divested its Netherlands facilities to AVS Bio to further sharpen its focus on AI-driven innovation. Notable collaborations include a strategic partnership valued at $8-10 million with an undisclosed leading biotech company for the development of novel cancer therapeutics, specifically Antibody-Drug Conjugates (ADCs) and bispecific antibodies, utilizing its B-cell Select™ platform and AI capabilities. ImmunoPrecise also partnered with RIBOPRO to advance mRNA-driven antibody discovery and with Aldevron, LLC to optimize GLP-1 alternatives for nucleic acid-based expression systems. The company has made breakthroughs in AI-designed GLP-1 therapies, demonstrating comparable or superior receptor activation to existing treatments, and advanced its AI-discovered universal dengue vaccine initiative into preclinical antibody generation. Its unique value proposition lies in combining decades of wet-lab expertise with cutting-edge AI and multi-omics modeling to offer an integrated, end-to-end platform that aims to accelerate and de-risk the discovery and development of novel biotherapeutics with enhanced precision and efficiency. Established in 1983, the company is headquartered in Austin, Texas.
The Biology Came First.
Atlas AI Labs to Launch First Ever Permissionless Asset-Backed Token from Dubai
Blue Point Brewing Launches Magic Hour IPA—A Bright, Tropical 6% ABV Sipper for Golden Hour
SweetWater Introduces Big Trip Double IPA: A Bold New Craft Beer
Dogfish Head Puts January's Pressures on Ice with “30 Minute Time Bank” Pop-Up
Hop Valley Brewing and Oregon Athletics Announce the Launch of Dang Green IPA, the First Official Craft Beer for the Oregon Ducks
ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT”
Flyers' Garnet Hathaway Launches Engine 19 IPA with Dogfish Head Craft Brewery to Support Local First Responders
AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation
ImmunoPrecise (IPA) Q4 2025 Earnings Transcript
ImmunoPrecise Antibodies Ltd. (IPA) Q4 2025 Earnings Conference Call Transcript
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q4 Loss, Lags Revenue Estimates
ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA
ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic
ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025
ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement
ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors
ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data